Text Size

A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis

Lazzaro C, van Steen C, Ghirelli G, Sacchi M, Sisto D, Uva M, Varano L, Angelillo L

  • 2023
  • Expert review of pharmacoeconomics & outcomes research
View publication
  • Therapeutic Area


  • Categories

    Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

  • Affiliations

    Pharmacoeconomics and Health Economics Department, Studio di Economia Sanitaria, Milan, Italy; School of Pharmacology, Biology and Biotechnologies Department "Lazzaro Spallanzani," University of Pavia, Pavia, Italy; Santen GmbH, München, Germany; Hospital ophthalmology unit, Italian National Health Service-endorsed hospital "San Pietro", Rome, Italy; University Eye Clinic, San Giuseppe Hospital, Multimedica, Milan, Italy; Academic ophthalmology unit, Azienda Ospedaliera Universitaria "Policlinico di Bari", Bari, Italy; Academic ophthalmology unit, Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco", Catania, Italy; Hospital ophthalmology unit, Private eye clinic "Villa Richeldi", Carpi, Italy

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022